English
English Chinese Simplified Chinese Traditional French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
📢 Meet LBT at ChinaHospeq 2026!
Marketing Campaign
News Categories
Featured News
LBT LB-20 Medical Cyclotron Supports Clinical PET Imaging and Radiopharmaceutical Research in Xi’an, China
LBT LB-20 Medical Cyclotron Supports ...
What Makes RDC Development So Challenging? From Molecular Design to Cyclotron Radionuclide Production
What Makes RDC Development So Challen...
Expanding PET Radiopharmaceutical Production in Burkina Faso with an LBT 11 MeV Medical Cyclotron
Expanding PET Radiopharmaceutical Pro...
RDC vs ADC: What Makes Radionuclides a Unique Therapeutic Payload? 🎯 ADC and RDC share a similar idea: use a targeting molecule to find the tumor, then let the payload do the killing. But their thera
RDC vs ADC: What Makes Radionuclides ...
Beyond ¹⁷⁷Lu and ²²⁵Ac: Where Are Next-Generation Therapeutic Radionuclides Heading?
Beyond ¹⁷⁷Lu and ²²⁵Ac: Where Are Nex...
β vs α: Why Are There Two Different Routes in Radionuclide Therapy?
β vs α: Why Are There Two Different R...
Why Do Diagnostic and Therapeutic Radionuclides Need to Be Matched?
Why Do Diagnostic and Therapeutic Rad...
From Imaging to Therapy: How Radioactive Decay Shapes Clinical Use
From Imaging to Therapy: How Radioact...
From Seeing Disease to Treating It: Why Radiopharmaceuticals Matter
From Seeing Disease to Treating It: W...
🧪 When a Pharmaceutical Company Builds Its Own Radionuclide Production Capability
🧪 When a Pharmaceutical Company Build...
0102030405

📢 Meet LBT at ChinaHospeq 2026!

2026-08-07
📢 Meet LBT at ChinaHospeq 2026!
Longevous Beamtech (LBT) is excited to participate in ChinaHospeq 2026, taking place on August 14–16, 2026, at the National Convention Center in Beijing, China.
📍 Event Information 📅 Date: August 14–16, 2026 📌 Venue: National Convention Center, Beijing, China 🏢 Booth: S45
At the exhibition, LBT will showcase advanced solutions for nuclear medicine, including medical cyclotron technology and radiopharmaceutical production solutions designed to support reliable operation, regulatory compliance, and evolving clinical needs.
We look forward to connecting with healthcare professionals, research institutions, and industry partners to exchange insights and explore opportunities for collaboration.
✨ See you at Booth S45!